Cargando…
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
Chondrosarcoma is a common primary bone malignancy whose phenotype increases with its histologic grade. They are relatively resistant to chemotherapy and radiation therapy limiting curative options for disseminated disease. Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell surface proteoglycan th...
Autores principales: | Nota, Sjoerd P. F. T., Osei-Hwedieh, David O., Drum, David L., Wang, Xinhui, Sabbatino, Francesco, Ferrone, Soldano, Schwab, Joseph H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468862/ https://www.ncbi.nlm.nih.gov/pubmed/36110930 http://dx.doi.org/10.3389/fonc.2022.939166 |
Ejemplares similares
-
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2021) -
Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts
por: Fenton, Moon, et al.
Publicado: (2015) -
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
por: Yang, Jianbo, et al.
Publicado: (2004) -
(212)Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
por: Kasten, Benjamin B., et al.
Publicado: (2018) -
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
por: Nounamo, Bernice, et al.
Publicado: (2023)